Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC28A3 | Q9HAS3 | 3/20 | 0.69 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.63 |
| ▸ | TYR | P14679 | 3/20 | 0.61 |
| ▸ | ATM | Q13315 | 1/20 | 0.59 |
| ▸ | SLC5A2 | P31639 | 5/20 | 0.59 |
| ▸ | SLC5A1 | P13866 | 3/20 | 0.57 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.53 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7181752 | 1.00 | SLC28A3 (0.69) | SLC28A3HIF1ATYRATMSLC5A2 | |
| SCHEMBL3664789 | 1.00 | SLC28A3 (0.69) | SLC28A3HIF1ATYRATMSLC5A2 | |
| SCHEMBL8657750 | 1.00 | SLC28A3 (0.69) | SLC28A3HIF1ATYRATMSLC5A2 | |
| SCHEMBL2923796 | 1.00 | SLC28A3 (0.69) | SLC28A3HIF1ATYRATMSLC5A2 | |
| SCHEMBL166162 | 1.00 | SLC28A3 (0.69) | SLC28A3HIF1ATYRATMSLC5A2 | |
| SCHEMBL2917655 | 0.98 | SLC28A3 (0.68) | SLC28A3HIF1ATYRATMSLC5A2 | |
| SCHEMBL13324378 | 0.98 | SLC28A3 (0.68) | SLC28A3HIF1ATYRATMSLC5A2 | |
| SCHEMBL2927767 | 0.98 | SLC28A3 (0.68) | SLC28A3HIF1ATYRATMSLC5A2 | |
| SCHEMBL3662700 | 0.98 | SLC28A3 (0.68) | SLC28A3HIF1ATYRATMSLC5A2 | |
| SCHEMBL12610461 | 0.89 | SLC28A3 (0.71) | SLC28A3HIF1ATYRATMSLC5A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-103977013-A | Application of catechol glycoside compounds to early-stage Alzhemier's disease | CUI DEHUA | 2014-08-13 | — | — | CN | claimed |
| CN-119314586-A | Screening method and application of gamma-secretase inhibitor | 沈阳医学院 | 2025-01-14 | — | — | CN | disclosed |
| CN-108530496-A | Malic acid glucosyloxy benzyl ester compound, preparation method and its application of the one kind for treating hepatic injury | 北京理工大学 | 2018-09-14 | — | — | CN | disclosed |
| US-9828407-B2 | Water soluble and activable phenolic derivatives with dermocosmetic and therapeutic applications and process for preparing said derivatives | LIBRAGEN (FR) | 2017-11-28 | — | — | US | disclosed |
| US-20150067920-A1 | PLANTS WITH INCREASED STRESS TOLERANCE | NATIONAL SCIENCE FOUNDATION | 2015-03-05 | — | — | US | disclosed |
| CN-103977013-A | Application of catechol glycoside compounds to early-stage Alzhemier's disease | CUI DEHUA | 2014-08-13 | — | — | CN | disclosed |
| US-20140088030-A1 | WATER SOLUBLE AND ACTIVABLE PHENOLICS DERIVATIVES WITH DERMOCOSMETIC AND THERAPEUTIC APPLICATIONS AND PROCESS FOR PREPARING SAID DERIVATIVES | LIBRAGEN (FR) | 2014-03-27 | — | — | US | disclosed |
| EP-2027279-B1 | Phenolic compounds with cosmetic and therapeutic applications | LIBRAGEN (FR) | 2012-04-18 | — | — | EP | disclosed |
| US-20090233876-A1 | Water Soluble and Activable Phenolics Derivatives with Dermocosmetic and Therapeutic Applications and Process for Preparing Said Derivatives | LIBRAGEN (FR) | 2009-09-17 | — | — | US | disclosed |
| EP-1867729-A1 | Water soluble phenolics derivatives with dermocosmetic and therapeutic applications | Libragen (FR) | 2007-12-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090233876-A1 | Water Soluble and Activable Phenolics Derivatives with Dermocosmetic and Therapeutic Applications and Process for Preparing Said Derivatives | UGGT1, TYR, LCT | SLC28A3 2244/4885HIF1A 937/4885TYR 2/4885 |
| US-20140088030-A1 | WATER SOLUBLE AND ACTIVABLE PHENOLICS DERIVATIVES WITH DERMOCOSMETIC AND THERAPEUTIC APPLICATIONS AND PROCESS FOR PREPARING SAID DERIVATIVES | UGGT1, TYR, G6PD | SLC28A3 2443/4885HIF1A 743/4885TYR 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.